- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Fund Finance
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Leveraged Finance
- Mergers and Acquisitions (M&A)
- Middle East and Islamic Finance and Investment
- Private Equity
- Public Companies
- Real Estate
- Structured Finance and Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- Innovation Protection
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Antitrust
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Corporate and Securities Litigation
- E-Discovery
- Global Construction and Infrastructure Disputes
- Innovation Protection
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy Transition
- Energy
- Financial Services
- Food and Beverage
- Higher Education
- Life Sciences and Healthcare
- Technology
- Artificial Intelligence (AI) and Machine Learning
- Buy American
- Crisis Management
- Doing Business in Latin America
- Environmental Agenda
- Environmental, Social and Governance (ESG)
- Focus on Women's Health
- Russia/Ukraine
- Special Purpose Acquisition Companies (SPACs)
- Careers
- News & Insights
- About
- Languages
Pharmaceutical and Medical Device
Insights 51 results
Client Alert
March 9, 2026
EUROPE – Revision of the EU General Pharmaceutical Legislation – Regulatory Protections
Client Alert
January 9, 2026
FDA Updates General Wellness and Clinical Decision Support Guidance Documents
Client Alert
December 29, 2025
Medicare and Medicaid Demos Seek to Impose MFN Pricing: An Overview of GENEROUS, GLOBE, and GUARD
Client Alert
December 22, 2025
EUROPE - Major Regulatory Developments in Pharmaceuticals, Biotechnology, and Medical Devices
Client Alert
December 19, 2025
President Trump Signs Executive Order to Reschedule Marijuana, Easing Research and Business Restrictions
Article · Source: Legal 500 Country Comparative Guides 2025
December 9, 2025
United States: Pharmaceutical Advertising
Article · Source: Financier Worldwide
October 16, 2025
Update to the European rules on advertising medicinal products
Client Alert
September 18, 2025
Maximizing The Term Of Patent Protection For Medical Devices
Client Alert
September 11, 2025
Advancing Novel Treatments for Rare Diseases: FDA Unveils and Previews New Efforts to Assess Therapies for Very Small Patient Populations
Client Alert
July 11, 2025
FDA Publishes More Than 200 Complete Response Letters (CRLs) With More to Come
Client Alert
July 3, 2025
European Court of Justice Restricts Advertising for Food with Botanicals
Client Alert
June 9, 2025
MultiPlan Algorithmic Pricing Antitrust Claims Survive Motion to Dismiss